Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
London pre-open: Stocks seen lower after weak US, European sessions
(Sharecast News) - London stocks were set to fall at the open on Tuesday following losses a day earlier in the US and Europe, as traders returned to their desks after the bank holiday. The FTSE 100 was called to open 12 points lower at 7,415.
CMC Markets analyst Michael Hewson said: "European markets got off to a negative start to the week yesterday with the UK out for the August bank holiday, while US markets also started the week lower, although the losses were fairly modest after Friday's big falls with the S&P500 finding some support just above the 50-day SMA and closing off its lows of the day.
"As we look at the return of UK markets, we can expect to see the FTSE100 open lower as markets here play catch-up, while we'll also get an insight into how higher inflation and interest rates is slowing demand for loans and mortgages in July."
On the macro front, net lending, consumer credit and mortgage approvals data for July are due out at 0930 BST.
Hewson said: "The effect of higher interest rates as well as the rising cost of living has already started to manifest itself in the most recent lending data. It's been a trend that has been in place since the start of this year, but appears to be accelerating as we head into the autumn.
"In June mortgage approvals slipped to their lowest levels in two years, coming in at 63.7k. Having seen a well flagged 50bps rate rise delivered in August and the possibility of another 50bps move at the very least in September, it's likely that we will probably see another slowdown in today's numbers.
"Net consumer credit was more resilient in June, jumping sharply to £1.8bn from £0.9bn in May, however this could be down to consumers loading up on debt to get by as monthly bills increase in size."
In corporate news, Bunzl posted a jump in first-half profit and revenue as product cost inflation and volume growth more than offset the expected decline in Covid-19 related sales.
In the six months to 30 June, adjusted pre-tax profit grew 12.2% to £411.4m, with revenues up 16.1% at £5.7bn.
Dechra Pharmaceuticals said it has bought California-based veterinary pharmaceutical manufacturer Med-Pharmex for $260m (£221.5m).
It said Med-Pharmex is the acquisition referred to in the fundraising announcement it made in July as the "potential acquisition".
Elsewhere, clinical trial results showed that AstraZeneca's Farxiga treatment against Type II diabetes significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction.
HFpeF is a condition in which the left ventricle of the heart hardens, becoming less able to relax, which in turn provokes higher blood pressure.
The results of the third phase clinical trial were presented at the European Society of Cardiology Congress 2022 on Tuesday, simultaneous to their publication in the New England Journal of Medicine.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.